KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amgen (AMGN) Research & Development (2016 - 2025)

Amgen has reported Research & Development over the past 17 years, most recently at $2.1 billion for Q4 2025.

  • Quarterly results put Research & Development at $2.1 billion for Q4 2025, up 24.25% from a year ago — trailing twelve months through Dec 2025 was $7.3 billion (up 21.93% YoY), and the annual figure for FY2025 was $7.3 billion, up 21.93%.
  • Research & Development for Q4 2025 was $2.1 billion at Amgen, up from $1.9 billion in the prior quarter.
  • Over the last five years, Research & Development for AMGN hit a ceiling of $2.1 billion in Q4 2025 and a floor of $959.0 million in Q1 2022.
  • Median Research & Development over the past 5 years was $1.3 billion (2021), compared with a mean of $1.4 billion.
  • Biggest five-year swings in Research & Development: dropped 21.8% in 2022 and later skyrocketed 34.38% in 2024.
  • Amgen's Research & Development stood at $1.3 billion in 2021, then decreased by 1.78% to $1.3 billion in 2022, then grew by 15.86% to $1.5 billion in 2023, then grew by 12.39% to $1.7 billion in 2024, then rose by 24.25% to $2.1 billion in 2025.
  • The last three reported values for Research & Development were $2.1 billion (Q4 2025), $1.9 billion (Q3 2025), and $1.7 billion (Q2 2025) per Business Quant data.